Trilaciclib not checked
Pharmacosmos A/S · G1T28 · CDK 4/6 inhibitor
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 2 in the EU
What this is
- How it works
- Blocks CDK enzymes that let cells divide, to slow the growth of cancer cells.-ciclib: cyclin-dependent kinase inhibitors WHO name stem
- How it’s given
- “250 mL of 5% dextrose in water or normal saline (0.9% sodium chloride solution)”In the company’s words, NCT07881705 on ClinicalTrials.gov
- Tested for
- Extensive-stage Small-cell Lung Cancer, Myelosuppression, Limited Stage Small Cell Lung Cancer
- Main trialPhase 4
- “This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.”In the company’s words, NCT05874401 on ClinicalTrials.gov
- Other names
- G1T28 · CDK 4/6 inhibitor · cyclin-dependent kinase 4/6 inhibitor
Other drugs for Extensive-stage Small-cell Lung Cancer
- PembrolizumabMerck & Co. · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Nanocrystalline Megestrol AcetateChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- ZG006Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3
Coming up3
- 15 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 5 Feb 2028Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 5 Feb 2028 | Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan | |
| Phase 3Active, not recruiting | 15 Jul 2027 | A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer | |
| Phase 3Recruiting | 31 Oct 2027 | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026